(Press-News.org) Using high-precision genetic tests to differentiate the thousands of bacteria that make up the human microbiome, researchers at NYU Langone Medical Center suggest that they have found a possible -- and potentially surprising -- root cause of the increased frequency of certain eye infections among contact lens wearers.
In a study report on their work to be presented at the annual meeting of the American Society for Microbiology on May 31 in New Orleans, NYU Langone researchers say they have identified a diverse set of microorganisms in the eyes of daily contact lens wearers that more closely resembles the group of microorganisms of their eyelid skin than the bacterial grouping typically found in the eyes of non-wearers.
Specifically, the NYU Langone team found that the eye surface, or conjunctiva, has surprisingly higher bacterial diversity than the skin directly beneath the eye and three times the usual proportion of Methylobacterium, Lactobacillus, Acinetobacter, and Pseudomonas bacteria in the eyes of the study's nine contact lens wearers than is typically found on the surface of the eyeballs of 11other men and women in the study who did not wear contact lenses. When measured and plotted on a graph, statistical germ diversity scores showed that the eye microbiome of contact lens wearers had a composition more similar to that of the wearer's skin than the eye microbiome of non-lens wearers.
"Our research clearly shows that putting a foreign object, such as a contact lens, on the eye is not a neutral act," says senior study investigator and NYU Langone microbiologist Maria Gloria Dominguez-Bello, PhD.
"What we hope our future experiments will show is whether these changes in the eye microbiome of lens wearers are due to fingers touching the eye, or from the lens's direct pressure affecting and altering the immune system in the eye and what bacteria are suppressed or are allowed to thrive," says Dominguez-Bello, an associate professor at NYU Langone.
"These findings should help scientists better understand the longstanding problem of why contact-lens wearers are more prone to eye infections than non-lens wearers," says Dominguez-Bello, whose research focuses on the different microbiomes of the gut and other body parts, how they interact, and how contemporary lifestyle practices may affect the microbiome and increase disease risk. Such understanding, she says, should point to better means of preventing infections.
"There has been an increase in the prevalence of corneal ulcers following the introduction of soft contact lenses in the 1970s," says study co-investigator Jack Dodick, MD, professor and chair of ophthalmology at NYU Langone. "A common pathogen implicated has been Pseudomonas. This study suggests that because the offending organisms seem to emanate from the skin, greater attention should be directed to eyelid and hand hygiene to decrease the incidence of this serious occurrence," he says.
As part of the study, researchers took hundreds of swabs of various parts of the eye, including the eye conjunctiva, as well as along the skin directly beneath the eye. Both swabs and used contact lenses were then subjected to genetic analysis in the lab to determine which bacteria were present.
While the bacterial composition in the eye of contact lens wearers more closely resembled that of the skin, some 5,245 distinct bacterial strains and subtypes were identified in the eye conjunctiva of lens wearers, and 5,592 strains were identified in the eyes of non-lens wearers. A similar but different composition of 2,133 strains and subtypes were identified in the skin directly beneath the eye of those with contact lenses, while 3,849 distinct bacteria were identified in non-lens wearers.
Surprisingly, researchers say, more Staphylococcus bacteria, which are linked to eye infections and more prominent on the skin - were found in the eyes of non-lens wearers, and researchers do not yet have an explanation for the disparity. Estimates vary, but many cases of potentially scarring bacterial keratitis, or eye inflammation, as well as conjunctival infections occur in contact lens wearers.
INFORMATION:
Funding support for the study, which took nearly two years to complete, was provided by the Research to Prevent Blindness Foundation. Besides Dominguez-Bello, other NYU Langone researchers involved in this study were lead investigator Hakdong Shin, PhD; Denni Catalano, MA, MB; Kenneth Price; Jack Dodick, MD; and Lisa Price, MD.
For more information, go to:
http://www.med.nyu.edu/biosketch/dominm05
http://gm.asm.org/
CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each ...
New Haven, Conn. -- Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.
Nearly 300,000 women in the United States are diagnosed with breast cancer each year; more than half undergo breast-conserving surgery with a partial mastectomy to remove the disease. However, between 20% and 40% of patients ...
CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
Investigators further found that pacritinib could be used safely in patients with myelofibrosis who ...
CHICAGO -- Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.
Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone.
The announcement was made at ...
Alexandria, VA - As this summer's blockbuster movie season gets underway, EARTH Magazine asks an important question: In movies, "are geologists portrayed as heroes or villains?" The topic of how geologists are portrayed in film has been oft-debated around a campfire, or over a frosty beverage at the end of a day of fieldwork, but now four scientists bring some serious analysis to the subject in the June issue feature, "Rock Stars - Geologists on the Silver Screen."
The authors - all geologists in the Department of Earth Sciences at the University of Gothenburg in Sweden ...
Hercules, CA -- May 29, 2015 -- Researchers at Harvard Medical School and the Digital Biology Center at Bio-Rad Laboratories, Inc. have developed a rapid, scalable, and cost-effective method for chromosomal phasing that provides researchers with a new method to determine if genetic variants are linked on the same chromosome. Using Bio-Rad's Droplet Digital PCR (ddPCRTM) technology, the Drop-Phase method can rapidly determine the chromosomal phase of allelic markers hundreds of kilobases apart. This ability may provide new insights into the cause, penetrance, and severity ...
In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.
Results of the trial with pembrolizumab, marketed as Keytruda, ...
The recent floods in Texas have caused some of the worst flooding since Hurricane Ike in 2008, causing the rainiest month in the state's history.
What lessons have been learned from Ike's devastation of the Galveston and Houston area, and how have they helped in the prediction of future such storms?
Researchers at the Institute for Computational Engineering and Sciences at the University of Texas at Austin have been studying computational models and simulations of hurricanes like Ike in order to predict the consequences of such natural disasters and better prepare ...
PHOENIX -- If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined.
In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.
One of the most common reasons people ...
At a traditional stone-laying ceremony outside La Serena, Chile on April 14th, construction officially began of the Large Synoptic Survey Telescope (LSST). This ambitious international astrophysics project is slated to start scanning the heavens in 2022. When it does, LSST should open up the "dark universe" of dark matter and dark energy--the unseen substance and force, respectively, composing 95 percent of the universe's mass and energy--as never before.
On April 2, 2015, the Director of LSST, Steven Kahn, along with astrophysicist Sarah Bridle and theoretical physicist ...
